A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Patients with mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexae (MLOA)
will be eligible for treatment with doxycycline (part A: clinico-pathological study);
patients with other types of ocular lymphoma, inflammatory lesions or those
ineligible/unwilling for treatment with doxycycline can participate in the only pathologic
study (part B).
Phase:
Phase 2
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)